6 Recommendations for data collection

6 Recommendations for data collection

6.1 As a condition of the positive recommendation and the managed access agreement, data on time on treatment, overall survival and baseline characteristics of people having venetoclax will be collected through the Systemic Anti-Cancer Therapy (SACT) dataset. The SACT dataset will also be used to collect time on treatment and overall survival data for people having ibrutinib and idelalisib in combination with rituximab, to inform a comparison with best supportive care (see section 4.35).

  • National Institute for Health and Care Excellence (NICE)